TIL
Developing TIL therapies to harness patients’ own immune cells for solid tumor treatment, combining cell expansion, GMP production and clinical translation.
Patient and tumor selection are critical first steps. The therapy is generally indicated for solid tumors with significant immune infiltration, such as melanoma, ovarian, or lung cancers. Patient eligibility is defined by tumor accessibility, overall health status, and prior treatment history.
Tumor tissue must be collected surgically under sterile and traceable conditions. The transport of the biopsy to the processing facility should occur rapidly and under controlled temperature to preserve lymphocyte viability. Proper labeling and documentation are essential for GMP compliance.
Tumor fragments are enzymatically and mechanically dissociated to release lymphocytes, which are then cultured in IL-2–enriched media. The goal of this phase is to allow outgrowth of tumor-reactive lymphocytes while maintaining cell diversity and functionality.
Early TIL cultures are tested for their tumor-specific reactivity and cytokine secretion. Flow cytometry and cytotoxicity assays help define cell composition, activation status, and the proportion of effector and memory T-cells that will influence the product’s potency.
TILs are evaluated in vitro for their ability to recognize and kill autologous or allogeneic tumor cells. These assays determine functional strength, specificity, and cytokine release profiles that support clinical translation.
Validated preclinical models, such as humanized xenografts or organoid systems, are used to confirm the anti-tumor activity and persistence of TILs. These studies also provide information on potential toxicities and dosing strategies.
All functional, safety, and persistence data are compiled into a package to support the Investigational Medicinal Product Dossier (IMPD) and clinical trial application, establishing the foundation for human use.
The REP defines how TILs are expanded to therapeutic doses. It involves stimulation with anti-CD3 antibodies and feeder cells under controlled GMP conditions. Process variables such as cytokine concentration, media composition, and timing are optimized for scalability and reproducibility.
Standardized assays are established to evaluate identity, purity, potency, and sterility. These include flow-cytometry-based phenotyping, viability assays, and functional potency tests aligned with regulatory expectations.
Cryogenic procedures are validated to ensure TIL stability during storage and shipment. This includes establishing freezing media, controlled-rate freezing, and thaw-recovery protocols to maintain product viability and functionality.
Once the tumor is received at the GMP facility, visual inspection, identity confirmation, and acceptance documentation are performed. Chain-of-custody and traceability systems guarantee compliance with GMP standards.
Pre-REP and REP processes are executed in Grade A/B environments using closed systems to prevent contamination. Expanded TILs are harvested, washed, and formulated in infusion buffer for patient administration.
All in-process and final QC tests—including sterility, endotoxin, mycoplasma, potency, and identity—are reviewed. The Qualified Person (QP) certifies the batch for clinical use after ensuring all GMP and regulatory criteria are met.
All GMP manufacturing caractheristics are compiled into a package to support the Investigational Medicinal Product Dossier (IMPD) and clinical trial application.
GMP has been adressed in other steps. This section focuses on GCP and interactions with the regulatory agencies during the application process and during the conduct of the trial. All the information relating to the product, its mode of action, its manufacturing, the target patient population, the clinical trial design, how the patients will be treated and followed up, mitigation of toxicities, data collection and analysis must be included in the IMPD that will be submited to the regulatory agencies.
It is crucial that developers build a solid understanding of the target population in their chosen disease area, through discussions with clinical investigators locally and abroad. In some cases, patient advocacy groups, or disease-specific organisations are also keen to become involved and can offer advice and data, sometimes of very high quality. It is important to understand the patient demographics, previous treatments they may have received and other options that may be available to them. The design of the trial should determine the target patient population.
The design of the first trial should determine the safety of the product, the optimal dose and ideally provide early signs of efficacy. Appropriate primary and secondary endpoints must therefore be determined. Subsequent trials will further evaluate efficacy and may include a control group, receiving the standard of care. The final (Pivotal) trial will generate the necessary data for marketing authorisation.
The execution of a clinical trial is a complex task that requires expertise and input on multiple fronts. It is also an expensive and time-consuming activity. Multiple stakeholders are needed at every step and precise coordination is needed.
CAR-T in oncology
Gene therapy development
CAR-T in inflammatory diseases
CAR-NK
